Stayble is a clinical stage pharmaceutical company developing the injectable treatment STA363 for disc hernia. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once, and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation.
The Company’s focus is set upon the continued clinical development of the ongoing clinical phase 1b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from pain caused by disc hernia.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Medicinaregatan 8a, Gothenburg,41390,sweden
- Phone
- +46 730 808 397
- in****@****yble.se
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- staybletherapeutics.se
- HQ
- Gothenburg
Stayble Therapeutics Questions
Stayble Therapeutics's helpline number is +46 730 808 397
Stayble Therapeutics's website is staybletherapeutics.se
Stayble Therapeutics's LinkedIn profile is https://se.linkedin.com/company/stayble-therapeutics
Stayble Therapeutics has
8 employees.
View email and phone details for 8
employees at Stayble Therapeutics.
Stayble Therapeutics's industry is
Pharmaceutical Manufacturing
Stayble Therapeutics's top competitors are
Toleranzia Ab,
Strike Pharma Ab,
Targinta Ab,
Isofol Medical Ab (Publ),
Cymab,
Ziccum Ab,
Synact Pharma,
Oblique Therapeutics Ab (Publ.),
Myopax,
Wntresearch Ab.
Stayble Therapeutics's support email address is info@stayble.se
Stayble Therapeutics's categories are Pharmaceutical Manufacturing
Stayble Therapeutics's founding year is 2015
